Access this article
We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.
References
Bischoff E . Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. Int J Impot Res 2004; 16(Suppl 1): S34–S37.
Cheitlin MD et al. Use of Sildenafil (Viagra) in patients with cardiovascular disease. J Am Coll Cardiol 1999; 33: 273–282.
Kloner RA . Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation 2004; 110: 3149–3155.
Gbekor E et al. Selectivity of sildenafil and other phosphodiesterase type 5 inhibitors against all human phosphodiesterase families. Eur Urol 2002; 1(Suppl 1): 63.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Weeks, J. Comment on: ‘Inhibition of phosphodiesterase 11 (PDE11) impacts on sperm quality’. Int J Impot Res 17, 387 (2005). https://doi.org/10.1038/sj.ijir.3901306
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijir.3901306
- Springer Nature Limited